ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 206 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2020. The put-call ratio across all filers is 0.50 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,949,935 | -43.7% | 391,303 | -27.1% | 0.00% | -40.0% |
| Q2 2023 | $24,759,284 | +38.7% | 536,728 | +20.6% | 0.01% | +25.0% |
| Q1 2023 | $17,844,800 | -65.4% | 445,007 | -60.1% | 0.00% | -66.7% |
| Q4 2022 | $51,626,375 | +23.3% | 1,114,318 | +10.2% | 0.01% | +20.0% |
| Q3 2022 | $41,874,000 | -18.4% | 1,011,188 | +17.6% | 0.01% | -16.7% |
| Q2 2022 | $51,313,000 | -7.9% | 860,075 | +12.1% | 0.01% | 0.0% |
| Q1 2022 | $55,717,000 | -8.7% | 767,241 | +5.7% | 0.01% | 0.0% |
| Q4 2021 | $61,023,000 | +33.7% | 725,678 | +43.4% | 0.01% | +20.0% |
| Q3 2021 | $45,655,000 | -25.5% | 506,208 | -21.2% | 0.01% | -28.6% |
| Q2 2021 | $61,277,000 | -36.6% | 642,650 | -24.3% | 0.01% | -44.0% |
| Q1 2021 | $96,669,000 | -27.5% | 849,021 | -11.9% | 0.02% | -26.5% |
| Q4 2020 | $133,409,000 | +271.0% | 963,728 | +120.3% | 0.03% | +240.0% |
| Q3 2020 | $35,957,000 | -9.2% | 437,496 | -13.5% | 0.01% | -23.1% |
| Q2 2020 | $39,579,000 | +44.8% | 505,990 | -17.7% | 0.01% | +30.0% |
| Q1 2020 | $27,325,000 | +14.8% | 615,022 | +10.3% | 0.01% | +100.0% |
| Q4 2019 | $23,806,000 | +40.6% | 557,406 | +40.8% | 0.01% | 0.0% |
| Q3 2019 | $16,937,000 | -34.0% | 395,924 | -2.0% | 0.01% | -28.6% |
| Q2 2019 | $25,666,000 | -25.3% | 404,180 | -18.4% | 0.01% | -30.0% |
| Q1 2019 | $34,361,000 | +162.7% | 495,409 | +64.7% | 0.01% | +150.0% |
| Q4 2018 | $13,081,000 | -43.7% | 300,867 | -1.2% | 0.00% | -33.3% |
| Q3 2018 | $23,238,000 | +24.6% | 304,410 | +25.5% | 0.01% | +20.0% |
| Q2 2018 | $18,651,000 | -30.7% | 242,640 | -54.0% | 0.01% | -28.6% |
| Q1 2018 | $26,910,000 | +8.1% | 527,748 | -1.7% | 0.01% | +40.0% |
| Q4 2017 | $24,902,000 | -36.7% | 536,932 | -27.3% | 0.01% | -50.0% |
| Q3 2017 | $39,323,000 | +7.4% | 738,311 | +25.2% | 0.01% | 0.0% |
| Q2 2017 | $36,630,000 | +29.5% | 589,761 | +41.3% | 0.01% | +25.0% |
| Q1 2017 | $28,294,000 | -0.1% | 417,440 | +3.6% | 0.01% | 0.0% |
| Q4 2016 | $28,325,000 | -41.0% | 402,857 | -40.5% | 0.01% | -42.9% |
| Q3 2016 | $47,999,000 | +49.5% | 676,618 | +3.1% | 0.01% | +40.0% |
| Q2 2016 | $32,106,000 | -9.4% | 656,433 | +17.3% | 0.01% | -16.7% |
| Q1 2016 | $35,432,000 | -32.3% | 559,647 | +20.0% | 0.01% | -25.0% |
| Q4 2015 | $52,321,000 | -31.5% | 466,398 | -41.2% | 0.02% | -36.0% |
| Q3 2015 | $76,373,000 | +192.9% | 792,989 | +211.4% | 0.02% | +212.5% |
| Q2 2015 | $26,075,000 | +66.9% | 254,665 | +1.2% | 0.01% | +100.0% |
| Q1 2015 | $15,620,000 | +22.3% | 251,572 | -13.6% | 0.00% | 0.0% |
| Q4 2014 | $12,773,000 | +8.0% | 291,102 | +39.3% | 0.00% | 0.0% |
| Q3 2014 | $11,828,000 | +38.8% | 208,973 | +10.1% | 0.00% | +33.3% |
| Q2 2014 | $8,523,000 | +39.4% | 189,863 | +51.8% | 0.00% | +50.0% |
| Q1 2014 | $6,114,000 | – | 125,048 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |